NASDAQ · TCBP
Healthcare · Biotechnology
$0.50
Up+$0.00 (+0.00%)
Updated Aug 15, 2026, 1:06 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
TCBP does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning TCBP.
TCBP research
Company profile and research snapshot.
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Dec 6, 2024 | HC Wainwright & Co. | Buy | — |
| Apr 27, 2023 | HC Wainwright & Co. | Buy | — |
| Jan 26, 2023 | HC Wainwright & Co. | Buy | — |
| Mar 28, 2022 | EF Hutton | Buy | — |
No generated briefing is available yet.
Benzinga · Mar 21, 2025
TC BioPharm (Holdings) PLC, a clinical-stage biotechnology company, announced that it will be delisted from the Nasdaq Stock Market due to failure to maintain a minimum bid price of $1.00 per share. The company's securities will be traded on the OTC Markets going forward.
Benzinga · Mar 18, 2025
TC BioPharm (Holdings) PLC announced initiatives to outsource several functions, move to a more decentralized model, and reduce its workforce by 20 employees. This is expected to reduce the company's core operational burn rate by approximately 55% compared to 2024.
GlobeNewswire Inc. · Mar 5, 2025
The CAR T-cell therapy pipeline is experiencing significant momentum, with over 180 companies actively developing more than 200 pipeline therapies. The report highlights promising pipeline candidates and recent advancements in the field, indicating the growing potential of this revolutionary cancer treatment approach.
Benzinga · Mar 5, 2025
TC BioPharm (Holdings) PLC announced a non-binding letter of intent to acquire a commercial-stage ophthalmic pharmaceutical company with an FDA-approved product for treating glaucoma and ocular hypertension. The acquisition is part of TC BioPharm's strategy to expand its therapeutic platform and bring in later-stage assets.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning TCBP.
No results
No recent SID articles mention TCBP.
